List of Excipients in Branded Drug SARCLISA

Sarclisa Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Sarclisa, the brand name for isatuximab-irfc, is an intravenous monoclonal antibody supplied as a 20 mg/mL concentrate. Its commercial excipient strategy is built around protein stabilization, low-volume refrigerated distribution, and compatibility with standard infusion systems. The main opportunity areas are improved ready-to-use presentation, subcutaneous delivery, biosimilar formulation development, and supply-chain differentiation for histidine buffer, sucrose, polysorbate 80, and container-closure systems.

What excipients are used in Sarclisa?

Sarclisa contains a conventional monoclonal-antibody formulation with histidine buffer, sucrose, polysorbate 80, and water for injection. The product is supplied in 100 mg/5 mL and 500 mg/25 mL single-dose vials at pH 6.0 (Sanofi, 2024a).

Component	Amount per mL	Primary formulation function
Isatuximab-irfc	20 mg	Anti-CD38 monoclonal antibody
L-histidine	1.0 mg	Buffering agent
L-histidine hydrochloride monohydrate	1.5 mg	Buffering and pH control
Sucrose	100 mg	Tonicity and protein stabilization
Polysorbate 80	0.2 mg	Reduces interfacial and agitation-induced aggregation
Water for injection	q.s.	Solvent

The formulation is preservative-free and intended for intravenous dilution. The product does not use a novel excipient system. Its commercial value lies in the balance between antibody stability, infusion compatibility, manufacturing robustness, and the ability to support a high-dose biologic regimen.

How does Sarclisa’s excipient system support product stability?

Histidine provides a relatively mild buffering environment suitable for antibody stability. The combination of L-histidine and histidine hydrochloride establishes the target pH and helps limit pH-driven aggregation or chemical degradation during refrigerated storage.

Sucrose contributes both tonicity and conformational stabilization. It reduces the tendency of the antibody to unfold during temperature changes, freeze-thaw exposure, and concentration operations. The 100 mg/mL concentration is consistent with a formulation designed to maintain protein stability without relying on a complex excipient mixture.

Polysorbate 80 protects the antibody at air-liquid, liquid-liquid, and container interfaces. This is important during vial filling, shipping, dilution, and infusion. The concentration is low, but polysorbate performance must be monitored because oxidation, hydrolysis, and interaction with product-contact surfaces can generate subvisible particles or affect antibody quality.

Why is polysorbate 80 commercially important?

Polysorbate 80 is a potential supply and quality-control constraint. Its degradation can produce free fatty acids and particulate matter. The risk increases with exposure to heat, light, oxygen, trace metals, and certain container surfaces.

For Sarclisa and comparable antibodies, commercial opportunities include:

• Higher-purity polysorbate 80 grades for biologics.
• Low-peroxide and low-particulate excipient grades.
• Tightly controlled fatty-acid profiles.
• Analytical packages covering oxidation, hydrolysis, and particle formation.
• Alternative surfactants such as polysorbate 20 or poloxamers, subject to comparability and clinical justification.

A substitution is not automatically a formulation improvement. Changing surfactant identity or concentration can affect aggregation, immunogenicity risk, extractables, adsorption, and infusion compatibility. A biosimilar developer would need to establish a product-quality relationship rather than rely on excipient sameness.

What is Sarclisa’s dosage form and administration profile?

Sarclisa is an intravenous concentrate. The approved regimen is weight-based, which creates operational and excipient requirements distinct from fixed-dose biologics.

The approved dose in combination with pomalidomide and dexamethasone is 10 mg/kg. It is administered weekly during the first treatment cycle and every two weeks thereafter. The carfilzomib and dexamethasone combination uses the same 10 mg/kg Sarclisa dose schedule in the applicable indication (Sanofi, 2024a).

At 20 mg/mL, the concentrate volume is approximately 0.5 mL per kilogram of patient body weight before dilution.

Patient weight	Approximate Sarclisa concentrate volume
60 kg	30 mL
70 kg	35 mL
80 kg	40 mL
90 kg	45 mL

The product is diluted in either 0.9% sodium chloride injection or 5% dextrose injection. The final diluted concentration is generally controlled within the product-label range, and the diluted solution is administered through an infusion system compatible with the approved preparation instructions (Sanofi, 2024a).

This creates commercial demand for:

• Low-sorption infusion bags and tubing.
• Compatible polyolefin, PVC, or equivalent administration materials.
• Standardized pharmacy-compounding systems.
• Reduced-volume dilution technologies.
• Ready-to-administer infusion formats.

What commercial opportunities exist for a Sarclisa ready-to-use formulation?

A ready-to-use product could reduce pharmacy preparation steps, dilution errors, drug wastage, and chair-time requirements. The opportunity is strongest in hospitals and oncology centers where high volumes of intravenous monoclonal antibodies are prepared each day.

Potential presentations include:

Presentation	Commercial advantage	Main technical barrier
Premixed infusion bag	Removes vial-to-bag transfer	Stability in the final container
Larger single-dose vial	Reduces vial handling	Higher wastage for lower-weight patients
Multi-vial dose pack	Supports weight-based dosing	Packaging and inventory complexity
High-concentration vial	Reduces infusion volume	Increased aggregation and viscosity risk
Frozen or lyophilized product	Potentially extends storage flexibility	Reconstitution burden and development cost
Automated compounding cartridge	Reduces preparation labor	Device compatibility and regulatory validation

A premixed bag would require robust in-use stability data, including antibody concentration, aggregation, subvisible particles, potency, sterility assurance, and container-closure integrity. The formulation would also need to remain stable during transport and time spent at the hospital before administration.

Can Sarclisa be reformulated for subcutaneous administration?

Subcutaneous delivery is the largest potential formulation opportunity. Intravenous Sarclisa requires weight-based dosing, infusion preparation, premedication, and observation for infusion-related reactions. A subcutaneous formulation could reduce administration time and improve treatment-site flexibility.

The technical challenge is dose volume. A 10 mg/kg dose for a 70 kg patient represents 700 mg of antibody. At the current 20 mg/mL concentration, that would require approximately 35 mL, which is generally too large for a single subcutaneous injection. A subcutaneous product would therefore require one or more of the following:

• A substantially higher antibody concentration.
• A recombinant human hyaluronidase-enabled delivery system.
• Multiple injection sites.
• A modified dosing schedule.
• A different loading and maintenance regimen.

Higher concentration increases viscosity and can accelerate aggregation, opalescence, particle formation, and injection-force problems. Increasing the concentration of sucrose or changing surfactant levels can also affect osmolality and local tolerability.

A subcutaneous product would create commercial value through:

• Shorter administration sessions.
• Lower infusion-center resource use.
• Potential home-administration models.
• Reduced dependence on infusion chairs.
• Differentiation from intravenous competitors.
• Improved convenience for long-term multiple myeloma treatment.

The development pathway would require clinical bridging and a full assessment of local tolerability, pharmacokinetics, immunogenicity, administration-device performance, and product comparability.

What excipient strategy is relevant to Sarclisa biosimilars?

Sarclisa is a biologic, so the relevant competitive pathway is biosimilar development under the Public Health Service Act, not an abbreviated new drug application based on an Orange Book-listed small molecule. The FDA regulates biosimilar applications under section 351(k), with analytical similarity forming the foundation of the development program (FDA, 2024a).

A biosimilar does not necessarily need to use the same inactive ingredients as the reference product. The developer must demonstrate that formulation differences do not produce clinically meaningful differences in safety, purity, or potency. For monoclonal antibodies, the central analytical package typically includes:

• Primary sequence confirmation.
• Higher-order structure.
• Glycosylation and charge variants.
• Aggregation and fragmentation.
• Particulate matter.
• Binding and biological activity.
• Forced-degradation behavior.
• Stability under intended storage and handling conditions.

The lowest-risk formulation strategy is usually to replicate the reference product’s excipient classes and approximate concentrations, subject to the developer’s manufacturing process and analytical results. A differentiated excipient system may offer manufacturing or stability advantages, but it increases comparability, justification, and regulatory risk.

Which excipient changes could create biosimilar differentiation?

Formulation change	Potential benefit	Main risk
Polysorbate 80 to polysorbate 20	Different degradation profile	Changed aggregation and immunogenicity profile
Sucrose replacement with trehalose	Alternative stabilization profile	Different tonicity and stability behavior
Histidine replacement with acetate or citrate	Process or pH flexibility	New degradation and tolerability profile
Higher surfactant concentration	Better interface protection	Increased degradation products
Lower surfactant concentration	Lower impurity burden	Greater particle and aggregation risk
Higher antibody concentration	Lower administration volume	Viscosity and subcutaneous delivery problems

For a biosimilar, excipient suppliers with strong lot-to-lot controls, peroxide specifications, elemental impurity controls, and biologics-specific analytical support are more commercially attractive than commodity suppliers.

What FDA regulatory status applies to Sarclisa?

Sarclisa received FDA approval in March 2020 with pomalidomide and dexamethasone for adults with relapsed or refractory multiple myeloma after at least two prior therapies, including lenalidomide and a proteasome inhibitor. The FDA later expanded the product’s use with carfilzomib and dexamethasone for adults with relapsed or refractory multiple myeloma after one to three prior lines of therapy (FDA, 2024b; Sanofi, 2024a).

Regulatory issue	Sarclisa status
Product type	Biologic monoclonal antibody
Active ingredient	Isatuximab-irfc
Dosage form	Intravenous infusion concentrate
FDA pathway	Biologics license application
Generic ANDA pathway	Not applicable
Orange Book listing	Not the principal patent reference for this biologic
Biosimilar pathway	Section 351(k)
FDA initial approval	March 2020
Key combinations	Pomalidomide/dexamethasone; carfilzomib/dexamethasone

The Purple Book and the biologics patent-dispute framework are more relevant than the Orange Book for biosimilar competition. Formulation patents, manufacturing patents, dosing patents, and device-related rights may still affect market entry, but the regulatory pathway is not based on a conventional Paragraph IV ANDA.

What patent and exclusivity issues affect Sarclisa excipient opportunities?

Excipient components such as histidine, sucrose, and polysorbate 80 are established pharmaceutical materials and are unlikely to provide meaningful standalone exclusivity around Sarclisa. The commercially relevant intellectual-property opportunities are more likely to involve:

• Specific concentration ranges.
• Stabilized antibody compositions.
• Low-particulate formulations.
• Container-closure combinations.
• Infusion-bag compatibility.
• High-concentration formulations.
• Subcutaneous delivery systems.
• Hyaluronidase-enabled administration.
• Manufacturing and purification methods.
• Dosing schedules and combination regimens.

A formulation patent may be valuable even when the underlying excipients are old, provided the claims cover a technically meaningful composition or performance characteristic. Patent strength depends on claim breadth, support in the specification, priority dates, prosecution history, validity risk, and the ability to design around the claimed excipient ranges.

No conventional Paragraph IV litigation analysis should be applied to Sarclisa as if it were a small-molecule Orange Book product. For future biosimilar competition, the relevant disputes may involve patent-listing procedures, notice of commercial marketing, declaratory actions, infringement litigation, and settlement terms under the biologics framework (Congressional Research Service, 2023).

How strong is the excipient-based commercial moat for Sarclisa?

The excipient moat is moderate for the marketed intravenous formulation and potentially stronger for an optimized subcutaneous or ready-to-use presentation.

Area	Commercial defensibility	Assessment
Histidine buffer	Low	Widely used and readily available
Sucrose stabilization	Low to moderate	Established excipient with broad precedent
Polysorbate 80 control	Moderate	Quality, degradation, and supply control matter
Exact formulation ranges	Moderate	May support composition claims
Vial and infusion compatibility	Moderate	Can create operational differentiation
Premixed infusion	Moderate to high	Requires substantial stability and packaging work
High-concentration formulation	Moderate to high	Technical barriers increase
Subcutaneous formulation	High potential	Requires concentration, device, and clinical development
Manufacturing process	Moderate to high	Process-specific and harder to reproduce
Biosimilar excipient package	Moderate	Analytical similarity limits differentiation

The strongest opportunities are not likely to come from selling generic sucrose or histidine. They are more likely to come from integrated solutions that combine biologics-grade excipients, analytical testing, container systems, and delivery devices.

What generic and biosimilar entry risks exist for Sarclisa?

Short-term competition is more likely to arise from competing multiple myeloma therapies than from a conventional generic launch. Relevant competitive products include other anti-CD38 antibodies, proteasome inhibitors, immunomodulatory agents, and emerging cellular or immune-engaging therapies.

A future isatuximab biosimilar could compete through:

• Lower acquisition cost.
• Preferred hospital formulary status.
• Contracting with oncology networks.
• Reduced preparation waste.
• Alternative vial sizes.
• Improved stability after dilution.
• A ready-to-use or subcutaneous presentation.

A biosimilar with the same intravenous presentation would face lower technical risk but less product differentiation. A reformulated product could create greater commercial value while requiring a larger clinical and regulatory investment.

What licensing opportunities exist around Sarclisa formulation technology?

Licensing opportunities are most credible in four areas.

Subcutaneous delivery

Hyaluronidase-enabled delivery platforms, high-concentration biologic formulation technologies, and large-volume injection systems could support a future subcutaneous isatuximab product.

Stability and aggregation control

Technologies that reduce polysorbate degradation, control particles, or improve stability during shipping could support lifecycle management and biosimilar development.

Container and device systems

Low-sorption bags, closed-system transfer devices, automated compounding platforms, and injection systems can reduce pharmacy labor and product loss.

Biosimilar development packages

Suppliers that offer reference-product characterization, excipient impurity profiling, and formulation screening can become strategic partners for future 351(k) developers.

Publicly disclosed licensing arrangements should be distinguished from technical platform availability. A delivery platform may be commercially relevant without being specifically licensed for Sarclisa.

Key Takeaways

• Sarclisa uses histidine buffer, sucrose, polysorbate 80, and water for injection in a 20 mg/mL intravenous formulation.
• The current excipient system is conventional but must control aggregation, particles, surfactant degradation, and container interaction.
• The principal commercial opportunities are ready-to-use infusion formats, high-concentration formulations, subcutaneous delivery, and biosimilar formulation development.
• Polysorbate 80 quality and degradation control are more commercially significant than the use of histidine or sucrose alone.
• Sarclisa is regulated as a biologic. Biosimilar competition follows the 351(k) pathway rather than a conventional Orange Book Paragraph IV process.
• Formulation and delivery patents may create lifecycle-management value even when the individual excipients are established and widely used.
• A subcutaneous presentation could generate the highest commercial differentiation but also carries the greatest formulation and clinical-development burden.

FAQs About Sarclisa Excipients and Commercial Strategy

Does Sarclisa contain polysorbate 80?

Yes. Sarclisa contains 0.2 mg/mL of polysorbate 80, which helps limit aggregation and adsorption at interfaces.

Is Sarclisa a lyophilized drug product?

No. Sarclisa is supplied as a liquid intravenous concentrate in single-dose vials.

Can sucrose be replaced in a Sarclisa biosimilar?

Potentially. A biosimilar developer may use a different stabilizer, but the change would require analytical and clinical justification showing no clinically meaningful difference from the reference product.

Why would a Sarclisa subcutaneous formulation need new excipients?

The current product is too dilute for efficient single-site subcutaneous delivery at weight-based doses. A subcutaneous version could require higher protein concentration, a delivery enzyme, modified surfactant control, or a different stabilization system.

What is the most attractive excipient business opportunity linked to Sarclisa?

The strongest opportunity is an integrated biologics formulation and delivery platform that supports higher concentration, lower particle formation, improved polysorbate stability, and subcutaneous or ready-to-use administration.

References

1. Congressional Research Service. (2023). Biosimilars: FDA regulatory, patent, and market issues. U.S. Congress.

2. International Council for Harmonisation. (1995). Q5C: Quality of biotechnological products: Stability testing of biotechnological/biological products.

3. International Council for Harmonisation. (2004). Q5E: Comparability of biotechnological/biological products subject to changes in their manufacturing process.

4. International Council for Harmonisation. (1999). Q6B: Specifications: Test procedures and acceptance criteria for biotechnological/biological products.

5. Sanofi. (2024a). Sarclisa (isatuximab-irfc) injection, for intravenous use: Prescribing information. U.S. Food and Drug Administration.

6. U.S. Food and Drug Administration. (2024a). Biosimilar and interchangeable biosimilar products. FDA.

7. U.S. Food and Drug Administration. (2024b). FDA approves isatuximab-irfc with carfilzomib and dexamethasone for multiple myeloma. FDA.

8. U.S. Food and Drug Administration. (2024c). Purple Book: Database of licensed biological products. FDA.